Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies
ALAMEDA, Calif. & KRAKOW, Poland--(BUSINESS WIRE)--Jul 7, 2022--
ALAMEDA, Calif. & KRAKOW, Poland--(BUSINESS WIRE)--Jul 7, 2022--